Our history

As part of the Kowa family of companies, we have more than 120 years of experience in business we can call upon and we are proud of our Japanese influence and heritage. Our experience not only encompasses pharmaceutical medicine development and marketing but also development of medical devices as well as experience in construction, the leisure industry, energy conservation and the environment.

Kowa our history 1984


Kowa company founded as the Hattori Kanesaburo Wholesale Store


Pharmaceutical division is established


Tokyo research laboratory and Fuji manufacturing plant founded


Hamamatsu Medical equipment manufacturing site built


Kowa Pharmaceutical Europe Company Ltd. Established in Wokingham UK


Livalo (Pitavastatin) for the treatment of dyslipidemia launched in Japan


Kowa launch their Intraocular lens franchise: Avansee TM


US and European launch of Pitavastatin

Kowa Girl with eye drops. Doctor hands applying eyewash. Recovery cataract procedure. Conjunctivitis treatment. Health ophthalmic concept. Ophthalmology clinic. Anti allergic drug.


Glanatec® (ripasudil) launched in Japan, first-in-class rho kinase inhibitor for the treatment of glaucoma and ocular hypertension.


Parmodia (Pemafibrate) launched in Japan for the reduction of high triglycerides in patients suffering dyslipidaemia and begins Global cardiovascular outcomes trial Prominent


Kowa company has more than 6500 employees worldwide, sales in excess of $3.5Bn and global businesses encompassing both trading and manufacturing.

Report adverse event

Kowa routinely monitors the safety of all its medicines. This includes review of safety data from clinical studies, and collection of reports and cases of adverse events for marketed products.

Patients and Volunteers in clinical trials reporting an adverse event must contact the investigator.

For specific medical information requests please visit the relevant product page to get in touch.

For the reporting of Livazo adverse events within Europe Union please contact local distributor or Recordati

For the reporting of Livazo adverse events within Middle East and North Africa (MENA) please contact...

Contact us

    I confirm I have read and accept the terms of the Privacy policy